A Phase IB/III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib Versus Placebo and Ruxolitinib in Patients With Intermediate- or High-Risk Myelofibrosis

Trial Profile

A Phase IB/III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib Versus Placebo and Ruxolitinib in Patients With Intermediate- or High-Risk Myelofibrosis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Vismodegib (Primary) ; Ruxolitinib
  • Indications Myelofibrosis
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 26 Jul 2017 Planned End Date changed from 1 Nov 2019 to 13 Dec 2019.
    • 26 Jul 2017 Planned primary completion date changed from 1 Nov 2019 to 13 Dec 2019.
    • 06 Jul 2017 This trial has been Discontinued in Germany, according to European Clinical Trials Database
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top